Curious about the company that's making headlines this morning?
The company posted a stronger-than-expected second quarter for 2019 and boosted its full-year sales outlook as international pharmaceutical revenues offset a domestic pullback.
Here are some other highlights:
- Adjusted diluted earnings for the three months ending in June 2019 came in at $2.58 per share, up 22.8% from the same period last year.
- Reported group revenues fell 1.3% to $20.56 billion but beat analysts' forecasts of $20.39 billion.
- Looking into 2019, operational sales are to grow to 3.7%, up from a prior forecast of between 2% and 3%, guiding for a topline of $82.4 billion to $83.2 billion.
- U.S consumer sales rose 4.1% to $1.537 billion, but domestic pharmaceutical sales fell 2% to $5.78 billion.
Watch the video to learn about the company's history and how it became what it is today.